Advanced Database for Biomaterials with Data Analysis and Visualisation Tools extended by a Marketplace with Digital Advisors

Acronym

BIOMATDB

Description of the granted funding

Biomaterials in healthcare span almost all medical fields, ranging from recognised materials to high-innovative smart and multi-functional biomaterials. One of the main challenges is to provide accessible and well-structured data of biomaterials for all relevant practitioners and user groups. BIOMATDB aims to create an advanced database for biomaterials providing detailed information on its properties. Flexible data analysis and visualisation tools support the search and selection process based on analyses of the results of biological testing of biomaterials from the scientific literature to incorporate data on as many of the material properties as possible. BIOMATDB also provides a web-optimised information marketplace and digital advisors to support companies, especially SMEs, in offering their products and properly presenting themselves at global scale. Initiated by biomaterial use cases, the web application will match the suppliers and demanders through intelligent matching tools and step-by-step decision support. BIOMATDB focuses on the creation of a label of biocompatibility to define the suitability of a biomaterial for use in a medical device or advanced therapy and to assist companies, especially SMEs, in choosing and facilitating market access for their products providing them a better guidance. All created technical systems and data processing methods are tested within existing open innovation testbeds and validation groups. Intuitive training manuals and compact online video tutorials support the use of the database, marketplace and label. Appropriate business models are derived for securing the long-term sustainability of the created solutions. The project has a significant impact on the findability and searchability of existing biomaterials at the pan-European level. It is an enabler for better uptake of biomaterials in future health applications and medical therapies.
Show more

Starting year

2022

End year

2024

Granted funding

142 687 €
Participant
MINDS & SPARKS GMBH (AT)
342 000 €
Participant
CLUST ER INDUSTRIE DELLA SALUTE E DEL BENESSERE (IT)
172 500 €
Participant
ECHALLIANCE COMPANY LIMITED BY GUARANTEE (IE)
89 250 €
Participant
FUNDACION PARA LA INVESTIGACION BIOMEDICA HOSPITAL INFANTIL UNIVERSITARIO NINO JESUS (ES)
92 500 €
Participant
SYNYO GmbH (AT)
674 375 €
Coordinator
ZACHODNIOPOMORSKI UNIWERSYTET TECHNOLOGICZNY W SZCZECINIE (PL)
126 250 €
Participant
BARCELONA SUPERCOMPUTING CENTER - CENTRO NACIONAL DE SUPERCOMPUTACION (ES)
379 375 €
Participant
CEC - CONSELHO EMPRESARIAL DO CENTRO/CIC - CAMARA DE COMERCIO E INDUSTRIA DO CENTRO (PT)
126 750 €
Participant
UNIVERSITETET I OSLO (NO)
289 712 €
Participant
UNIVERSITAT POLITECNICA DE CATALUNYA (ES)
239 000 €
Participant
NATIONAL UNIVERSITY OF IRELAND GALWAY (IE)
124 750 €
Participant

Amount granted

2 799 149 €

Funder

European Union

Funding instrument

HORIZON Coordination and Support Actions

Framework programme

Horizon Europe (HORIZON)

Call

Programme part
Digital, Industry and Space (11704)
Advanced Materials (11708)
Topic
Biomaterials database for Health Applications (CSA) (HORIZON-CL4-2021-RESILIENCE-01-25)
Call ID
HORIZON-CL4-2021-RESILIENCE-01

Other information

Funding decision number

101058779

Identified topics

bioinformatics